TherapeuticsMD Inc (TXMD) - Total Assets
Based on the latest financial reports, TherapeuticsMD Inc (TXMD) holds total assets worth $38.67 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of TherapeuticsMD Inc for net asset value and shareholders' equity analysis.
TherapeuticsMD Inc - Total Assets Trend (1994–2024)
This chart illustrates how TherapeuticsMD Inc's total assets have evolved over time, based on quarterly financial data.
TherapeuticsMD Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
TherapeuticsMD Inc's total assets of $38.67 Million consist of 25.6% current assets and 74.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.0% |
| Accounts Receivable | $3.56 Million | 9.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.32 Million | 11.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1994–2024)
This chart illustrates how TherapeuticsMD Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TXMD market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TherapeuticsMD Inc's current assets represent 25.6% of total assets in 2024, an increase from 20.0% in 1994.
- Cash Position: Cash and equivalents constituted 13.0% of total assets in 2024, up from 4.5% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 1994.
- Asset Diversification: The largest asset category is intangible assets at 11.1% of total assets.
TherapeuticsMD Inc Competitors by Total Assets
Key competitors of TherapeuticsMD Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
TherapeuticsMD Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.46 | 2.03 | 2.17 |
| Quick Ratio | 2.46 | 2.03 | 2.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.22 Million | $6.18 Million | $69.17 Million |
TherapeuticsMD Inc - Advanced Valuation Insights
This section examines the relationship between TherapeuticsMD Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.95 |
| Latest Market Cap to Assets Ratio | 0.62 |
| Asset Growth Rate (YoY) | -10.4% |
| Total Assets | $38.82 Million |
| Market Capitalization | $23.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values TherapeuticsMD Inc's assets below their book value (0.62x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: TherapeuticsMD Inc's assets decreased by 10.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for TherapeuticsMD Inc (1994–2024)
The table below shows the annual total assets of TherapeuticsMD Inc from 1994 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $38.82 Million | -10.36% |
| 2023-12-31 | $43.31 Million | -52.12% |
| 2022-12-31 | $90.46 Million | -46.62% |
| 2021-12-31 | $169.47 Million | -6.68% |
| 2020-12-31 | $181.61 Million | -31.72% |
| 2019-12-31 | $265.99 Million | +25.47% |
| 2018-12-31 | $211.98 Million | +48.00% |
| 2017-12-31 | $143.23 Million | +0.53% |
| 2016-12-31 | $142.47 Million | +93.24% |
| 2015-12-31 | $73.73 Million | +24.80% |
| 2014-12-31 | $59.08 Million | -4.74% |
| 2013-12-31 | $62.02 Million | +965.92% |
| 2012-12-31 | $5.82 Million | +304.39% |
| 2011-12-31 | $1.44 Million | +207.80% |
| 2010-12-31 | $467.42K | -44.99% |
| 2009-12-31 | $849.76K | +1461.52% |
| 2008-12-31 | $54.42K | -89.01% |
| 2007-12-31 | $495.36K | -73.47% |
| 2006-12-31 | $1.87 Million | +3.30% |
| 2005-12-31 | $1.81 Million | +66.05% |
| 2004-12-31 | $1.09 Million | +21.19% |
| 2003-12-31 | $898.22K | +19.25% |
| 2002-12-31 | $753.21K | +8.36% |
| 2001-12-31 | $695.12K | +10.66% |
| 2000-12-31 | $628.17K | +26.10% |
| 1999-12-31 | $498.16K | -2.10% |
| 1998-12-31 | $508.85K | +0.79% |
| 1997-12-31 | $504.88K | -2.10% |
| 1996-12-31 | $515.70K | +2.12% |
| 1995-12-31 | $505.02K | +17.36% |
| 1994-12-31 | $430.33K | -- |
About TherapeuticsMD Inc
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors an… Read more